

## NEW CONTRACT AMENDMENT FOR ALOXI

MGI PHARMA offers a new contract amendment to OA's product agreement for Aloxi, which runs until December 31, 2006. The agreement offers a new contract price, as well as individual unit market share additional discounts and individual unit market share rebates.



Unit Market Share %	Additional Discount %*
0-19.9% MS	0%
20.0-49.9% MS	6%
50.0-100% MS	12%

\*The additional discount will be in the form of a discounted price

The first market share measurement period will be October 1 – March 31, 2006. Market share will be measured every six-months thereafter (April 1 – September 30, October 1 – March 31).

Unit Market Share %	Additional Discount %*
0-69.9% MS	0%
70.0-100% MS	5%

\*The additional discount rebate will be in the form of a credit memo to the specialty distributor.

The first Market share measurement period will be October 1 – September 30, 2006. Market share will be measured annually thereafter (October 1 – September 30).

For any questions regarding this contract amendment, contact your local MGI PHARMA representative or OA at **888-732-7352**.

## SUPERGEN, INC. AWARDS OA PRODUCT AGREEMENT FOR NIPENT®

The agreement for Nipent® runs from January 1, 2006 to December 31, 2006.



“Our relationship with SuperGen gives OA members many clinical trial opportunities with a company dedicated to serving the needs of community based oncologists,” says Brent Evans, OA Executive Vice President and General Manager.

Nipent® is indicated as a single-agent treatment for both untreated and alpha-interferon-refractory hairy cell leukemia patients with active disease as defined by clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms.

**Nipent® (pentostatin for injection), NDC # 62701-0800-01, comes in a vial size of 5mL (sdv) with a strength of 10mg.**

## NEW KYTRIL AND XELODA AGREEMENT FOR 2006

Oncology Associates is pleased to announce the continuation of our Roche agreement for Kytril (Granisetron Hydrochloride) and XELODA (Capecitabine). The terms of this contract extension will continue through December 31, 2007 and OA members will not need to resign in order to receive valuable savings. Please consider the benefits that Kytril offers through this agreement on both the commercial and Medicare side. Also, consider Xeloda's clinical benefits to your patients and the freedom it may provide while on their chemotherapy regimens as well as its inclusion into the 2006 demonstration projects.

